Skip Navigation

Bioscience Horizons 2008 1(1):1-8; doi:10.1093/biohorizons/hzn001
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Atkin, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Atkin, L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008

Rosiglitazone-induced SERCA2b inhibition: implications for monocyte cytoskeletal remodelling and diabetic microangiopathy

Lisa Atkin*

University of Wales Institute Cardiff (UWIC), Cardiff, UK

* Corresponding author: No. 1, Mitre Court, Llandaff, Cardiff CF5 2EZ, UK. Tel: 0778 7768935. Email: l.j.atkin{at}uwic.ac.uk

Supervisor: Dr Richard Webb, University of Wales Institute Cardiff (UWIC), Cardiff, UK.


   Abstract

In type 2 diabetes, exposure of monocytic cells to inflammatory stimuli can lead to aberrant cytoskeletal remodelling and contribute to the development of diabetic microangiopathy. Previous studies within our research group have demonstrated that Rosiglitazone significantly reduces formyl-methionyl-leucyl-proline (f-MLP)-induced actin polymerization in monocytes by increasing cytosolic calcium ion concentrations ([Ca2+]i) in both resting and f-MLP-stimulated cells. As the timescale of this effect resembled inhibition of SERCA2b, the ‘housekeeping’ Ca2+ pump enzyme that sequesters Ca2+ into the ER compensatory to non-specific leakage into the cytoplasm, the present study sought to test the hypothesis that Rosiglitazone-induced increases in [Ca2+]i are brought about by inhibition of SERCA2b, and also investigated how such changes are transduced into cytoskeletal remodelling.

Coupled-enzyme Ca2+-ATPase assays revealed a SERCA2b activity of 49 ± 5 nmol/mg/min in monocytic microsomes but pre-incubation with Rosiglitazone (20 µM; 30 min) induced statistically significant inhibition of this activity (P < 0.05).

Permeabilization of cultured monocytes in external solutions containing differing [Ca2+]free was used to manipulate [Ca2+]i, and F-actin content measured using flow cytometric analysis of FITC-phalloidin fluorescence. At [Ca2+]i >100 nM, a significant decrease in cells' F-actin content was observed (P < 0.05). In conditions of minimal [Ca2+]i, f-MLP exerted a polymerizing effect on the actin cytoskeleton; however, as [Ca2+]i was increased to >100 nM, this polymerizing effect was significantly reduced.

Finally, as a literature search identified the Ca2+-dependent actin-modulating protein gelsolin as a candidate for transducing changes in [Ca2+]i into actin cytoskeletal remodelling, western blot experiments using anti-gelsolin antibodies were used to detect ~88 kDa immunogenic bands in monocytic protein extracts, thus confirming the expression of gelsolin in monocytes.

In conclusion, the current study demonstrates the importance of [Ca2+]i in modulating actin cytoskeletal remodelling, and suggests that Rosiglitazone, via its ability to affect monocytic Ca2+ signalling processes, may confer a level of protection against the development of diabetic microangiopathy.

Key words: rosiglitazone, actin cytoskeleton, calcium, monocytes, gelsolin, diabetic microangiopathy


Submitted on 24 September 2007; accepted on 17 December 2007


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.